The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
List view / Grid view
Filter the results
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Preclinical studies suggest GBR 1302 may have activity against a range of HER2-expressing tumour types, including breast, gastric and other cancers...
Sanofi and Glenmark Pharmaceuticals sign license agreement on Novel Monoclonal Antibody for Crohn’s Disease
17 May 2011 | By Glenmark Pharmaceuticals
Sanofi to develop molecule for Crohn’s Disease & other anti-inflammatory conditions...